MyBody-X angle on Abnehmspritze Training

From MyBody-X’s perspective on ‚weight loss injection training‘ (GLP-1 agonists like semaglutide), the stance is cautious and evidence-aware. While certain genetic variants (e.g., in the GLP1R gene) have been linked to differential drug response in GWAS, effect sizes are small and predictive power for individuals is low. Direct-to-consumer tests claiming to predict ‚optimal response‘ overstate the utility of single SNPs. Most weight loss on GLP-1 drugs is driven by caloric restriction, behavioral change, and exercise – not genetics. These are prescription medications with side effects (nausea, pancreatitis). MyBody-X advises: use genetic tests as inspiration, not prescription. Consult a physician and combine the injection with a structured training and nutrition plan. Evidence for genetically personalized dosing or exercise recommendations is currently insufficient.